Literature DB >> 24772301

Clinicopathological characteristics of vascular endothelial growth factor expression in uveal melanoma: A meta-analysis.

Meng Yang1, Xiaocong Kuang2, Yanbin Pan3, Meile Tan3, Binzhu Lu3, Jian Lu3, Qiumei Cheng1, Jianmin Li3.   

Abstract

Angiogenesis is a potential prognostic factor that has been extensively investigated in patients with uveal melanoma (UM). Vascular endothelial growth factor (VEGF) expression is crucial in angiogenesis. However, there have been conflicting data regarding the clinicopathological data in UM. A meta-analysis was performed of all the germane literature to assess the clinicopathological characteristics of VEGF expression by combining separately estimated odds ratio (OR) values. Our combined results demonstrated that, according to the available studies, the expression of VEGF in UM was significantly higher compared to normal tissue [338 patients and 99 controls; OR=16.15, 95% confidence interval (CI): 8.65-30.12, P<0.00001]. When stratifying the studies by age (315 patients; OR=2.08, 95% CI: 1.19-3.62, P=0.01), cell type (423 patients; OR=0.54, 95% CI: 0.32-0.90, P=0.02), tumor size (222 patients; OR=0.30, 95% CI: 0.14-0.68, P=0.004) and scleral invasion (248 patients; OR=0.34, 95% CI: 0.15-0.78, P=0.01), significant clinicopathological information was provided. Our results indicated that VEGF expression in UM patients was significantly higher compared to that observed in controls. It was also significantly higher in patients who presented with scleral invasion and those who were aged <50 years. In addition, VEGF expression was higher in mixed-cell type and epithelioid-cell type UM and in patients with large-sized tumors.

Entities:  

Keywords:  angiogenesis; clinicopathological characteristics; uveal melanoma; vascular endothelial growth factor expression

Year:  2014        PMID: 24772301      PMCID: PMC3999140          DOI: 10.3892/mco.2014.247

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  22 in total

1.  VEGF as a biomarker for metastatic uveal melanoma in humans.

Authors:  Vivian Barak; Jacob Pe'er; Inna Kalickman; Shahar Frenkel
Journal:  Curr Eye Res       Date:  2011-02-01       Impact factor: 2.424

2.  Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth.

Authors:  S R Boyd; D S W Tan; L de Souza; M H Neale; N E Myatt; R A Alexander; M Robb; J L Hungerford; I A Cree
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

3.  Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.

Authors:  S Ugurel; G Rappl; W Tilgen; U Reinhold
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

4.  Expression of haematogenous and lymphogenous chemokine receptors and their ligands on uveal melanoma in association with liver metastasis.

Authors:  Bianca C Dobner; Aline I Riechardt; Antonia M Joussen; Stefan Englert; Nikolaos E Bechrakis
Journal:  Acta Ophthalmol       Date:  2012-11-20       Impact factor: 3.761

5.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.

Authors:  B Berse; L F Brown; L Van de Water; H F Dvorak; D R Senger
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

6.  COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.

Authors:  G Perrone; D Santini; B Vincenzi; M Zagami; A La Cesa; A Bianchi; V Altomare; A Primavera; C Battista; A Vetrani; G Tonini; C Rabitti
Journal:  Histopathology       Date:  2005-05       Impact factor: 5.087

Review 7.  Anti-angiogenic therapy in uveal melanoma.

Authors:  Mariam El Filali; Pieter A Van der Velden; Gregorius P M Luyten; Martine J Jager
Journal:  Dev Ophthalmol       Date:  2011-10-21

8.  Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma.

Authors:  R Clarijs; L Schalkwijk; D J Ruiter; R M de Waal
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-06       Impact factor: 4.799

9.  Predictive factors of visual outcome after local resection of choroidal melanoma.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

10.  [Correlation of tumor angiogenesis with clinicopathologic prognostic parameters in choroidal melanoma].

Authors:  Feng-hua Wang; Bin Li; Xian-li Sun; Liao-qing Li; Chang-xi Chen
Journal:  Zhonghua Yan Ke Za Zhi       Date:  2003-02
View more
  6 in total

1.  Growth of Uveal Melanoma following Intravitreal Bevacizumab.

Authors:  Jasmine H Francis; Jonathan Kim; Amy Lin; Robert Folberg; Saipriya Iyer; David H Abramson
Journal:  Ocul Oncol Pathol       Date:  2016-11-12

2.  Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.

Authors:  Amir Mahdjoubi; Marie Najean; Stéphanie Lemaitre; Sylvain Dureau; Rémi Dendale; Christine Levy; Livia Lumbroso-Le Rouic; Laurence Desjardins; Nathalie Cassoux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-07       Impact factor: 3.117

3.  Intravitreal triamcinolone acetate for radiation maculopathy recalcitrant to high-dose intravitreal bevacizumab.

Authors:  Richard I Kaplan; Sonal S Chaugule; Paul T Finger
Journal:  Br J Ophthalmol       Date:  2017-04-17       Impact factor: 4.638

4.  Fucoidan Does Not Exert Anti-Tumorigenic Effects on Uveal Melanoma Cell Lines.

Authors:  Michaela Dithmer; Anna-Maria Kirsch; Elisabeth Richert; Sabine Fuchs; Fanlu Wang; Harald Schmidt; Sarah E Coupland; Johann Roider; Alexa Klettner
Journal:  Mar Drugs       Date:  2017-06-22       Impact factor: 5.118

Review 5.  Hypoxia-dependent drivers of melanoma progression.

Authors:  Simona D'Aguanno; Fabiana Mallone; Donatella Del Bufalo; Antonietta Moramarco; Marco Marenco
Journal:  J Exp Clin Cancer Res       Date:  2021-05-08

6.  Treatment response to intravitreal bevacizumab in small pigmented choroidal lesions with subretinal fluid.

Authors:  Junwon Lee; Hee Jung Kwon; Min Kim; Christopher Seungkyu Lee; Sung Chul Lee
Journal:  BMC Ophthalmol       Date:  2019-05-03       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.